Management of Stage II Germ Cell Tumors.
暂无分享,去创建一个
[1] P. Albers,et al. Retroperitoneal lymph node dissection in the setting of elevated markers , 2018, Current opinion in urology.
[2] P. Albers,et al. The PRIMETEST trial – interim results of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in Stage II A/B seminoma patients without adjuvant treatment , 2018 .
[3] P. Warde,et al. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. , 2018, European urology focus.
[4] T. Masterson,et al. Modified retroperitoneal lymph node dissection for post‐chemotherapy residual tumour: a long‐term update , 2017, BJU international.
[5] P. Pierorazio,et al. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. , 2017, European urology.
[6] A. Jemal,et al. Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. , 2016, Practical radiation oncology.
[7] S. Beriwal,et al. Stage II Testicular Seminoma: Patterns of Care and Survival by Treatment Strategy. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).
[8] Terukazu Nakamura,et al. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors , 2016, International Journal of Clinical Oncology.
[9] L. Zaletel,et al. Treatment-related Cardiovascular Toxicity in Long-term Survivors of Testicular Cancer , 2016, Radiology and oncology.
[10] E. Castle,et al. Robot‐assisted retroperitoneal lymph node dissection in testicular cancer , 2015, Journal of surgical oncology.
[11] A. Horwich,et al. Guidelines on Testicular Cancer: 2015 Update. , 2015, European urology.
[12] F. Bladou,et al. External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer , 2014, World Journal of Urology.
[13] A. Horwich,et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Eggener,et al. Critical Evaluation of Modified Templates and Current Trends in Retroperitoneal Lymph Node Dissection , 2013, Current Urology Reports.
[15] S. Fosså,et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] L. Kavoussi,et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience. , 2012, The Journal of urology.
[17] A. Horwich,et al. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] B. Carver,et al. The role of lymphadenectomy for testicular cancer: indications, controversies, and complications. , 2011, The Urologic clinics of North America.
[19] S. Fosså,et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Daneshmand,et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Einhorn,et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. Schwartz,et al. NCCN clinical practice guidelines in oncology: testicular cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[23] Owen Kang,et al. Growing teratoma syndrome , 2008, International Journal of Gynecological Cancer.
[24] W. Brenner,et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. , 2008, The Journal of urology.
[25] R. Motzer,et al. Medical treatment of advanced testicular cancer. , 2008, JAMA.
[26] R. Motzer,et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] L. Kavoussi,et al. Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. , 2007, Urology.
[28] R. Motzer,et al. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] L. Einhorn,et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? , 2007, Cancer.
[30] S. Culine,et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] B. Carver,et al. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. , 2007, Urology.
[32] R. Motzer,et al. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. , 2007, The Journal of urology.
[33] B. Czerniak,et al. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer , 2006, Cancer.
[34] R. Motzer,et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. , 2006, The Journal of urology.
[35] J. Bacik,et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] J. Bacik,et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Motzer,et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. , 2005, The Journal of urology.
[38] C. Bokemeyer,et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. , 2005, European journal of radiology.
[39] S. Fosså,et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. Aparicio,et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Koch,et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. , 2004, The Journal of urology.
[42] R. Fimmers,et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. , 2004, The Journal of urology.
[43] J. Sheinfeld,et al. The role of retroperitoneal lymph node dissection in the management of testicular cancer. , 2004, Urologic oncology.
[44] M. D. De Santis,et al. The role of positron emission tomography in germ cell cancer , 2004, World Journal of Urology.
[45] C. Bokemeyer,et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] J. Bacik,et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] P. Kantoff,et al. Chemotherapy for teratoma with malignant transformation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] S. Culine,et al. Advanced seminoma—Treatment results and prognostic factors for survival after first‐line, cisplatin‐based chemotherapy and for patients with recurrent disease , 2003, Cancer.
[49] D P Dearnaley,et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] C. Meisner,et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] P. Biron,et al. Management of post-chemotherapy residual masses in advanced seminoma. , 2002, The Journal of urology.
[52] P. Warde,et al. Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. , 2002, The Canadian journal of urology.
[53] L. Kiemeney,et al. The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours , 2002, BJU international.
[54] A. Pollack,et al. Radiotherapy for stage II testicular seminoma. , 2001, International journal of radiation oncology, biology, physics.
[55] A. Horwich,et al. Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[56] G. Bartsch,et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. , 2000, The Journal of urology.
[57] L. Weissbach,et al. RPLND or Primary Chemotherapy in Clinical Stage IIA/B Nonseminomatous Germ Cell Tumors? , 2000, European Urology.
[58] L. Einhorn,et al. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. , 2000, European journal of cancer.
[59] R. Günther,et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. , 1999, Urology.
[60] P. Albers,et al. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. , 1999, Urology.
[61] Jewett Ma,et al. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. , 1998 .
[62] L. Einhorn,et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] S. Culine,et al. Cisplatin-based chemotherapy in advanced seminoma: the Institut Gustave Roussy experience. , 1998, European journal of cancer.
[64] R. Motzer,et al. Testicular germ-cell cancer. , 1997, The New England journal of medicine.
[65] R. Motzer,et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] P. Carroll,et al. A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group. , 1997, International journal of radiation oncology, biology, physics.
[67] L. Einhorn,et al. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] R. Motzer,et al. Surgery for a post-chemotherapy residual mass in seminoma. , 1997, The Journal of urology.
[69] P. Wilkinson,et al. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Richard Sylvester,et al. International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .
[71] S. Culine,et al. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis. , 1997, British journal of urology.
[72] R. Motzer,et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] J. Thornhill,et al. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. , 1995, European journal of cancer.
[74] J P Donohue,et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] G. Kerr,et al. Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. , 1995, The British journal of radiology.
[76] L. Einhorn,et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] J. Donohue,et al. Complications of primary retroperitoneal lymph node dissection. , 1994, The Journal of urology.
[78] N. Geller,et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] J. Thornhill,et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. , 1993, The Journal of urology.
[80] P. Sogani. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. , 1991, The Urologic clinics of North America.
[81] L. Einhorn,et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] J. Kearsley,et al. Radiotherapy for stage 2 testicular seminoma: the prognostic influence of tumor bulk. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] L. Einhorn,et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. , 1988, Annals of internal medicine.
[84] M. Gospodarowicz,et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. , 1988, The Journal of urology.
[85] D. Stablein,et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. , 1987, The New England journal of medicine.
[86] L. Weissbach,et al. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. , 1987, The Journal of urology.
[87] L. Einhorn,et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.
[88] G. Bartsch,et al. Nerve-preserving bilateral retroperitoneal lymphadenectomy: anatomical study and operative approach. , 1987, The Journal of urology.
[89] G. Pizzocaro. Retroperitoneal lymph node dissection in clinical stage IIA and IIB nonseminomatous germ cell tumours of the testis. , 1987, International journal of andrology.
[90] R. Salvioni,et al. Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. , 1985, The Journal of urology.
[91] P. Lange,et al. Fertility issues following therapy for testicular cancer. , 1984, Seminars in urology.
[92] J. Donohue,et al. Distribution of nodal metastases in nonseminomatous testis cancer. , 1982, The Journal of urology.
[93] P. Lange,et al. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. , 1982, The Journal of urology.
[94] J. Donohue,et al. Complications of retroperitoneal lymph node dissection. , 1981, The Journal of urology.
[95] D. Mcleod,et al. Radiation therapy: a primary treatment modality for seminoma. , 1980, The Urologic clinics of North America.
[96] S. Hajdu,et al. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors , 1974 .
[97] F. Hinman. THE OPERATIVE TREATMENT OF TUMORS OF THE TESTICLE: WITH THE REPORT OF THIRTY CASES TREATED BY ORCHIDECTOMY , 1914 .
[98] J. Dobson,et al. On the Injection of Lymphatics by Prussian Blue. , 1910, Journal of anatomy and physiology.
[99] Y. Lotan,et al. Impact of hospital case volume on testicular cancer outcomes and practice patterns. , 2018, Urologic oncology.
[100] P. Maroto,et al. Long-term toxicity of the treatment for germ cell-cancer. A review. , 2018, Critical reviews in oncology/hematology.
[101] P. Albers,et al. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma. , 2015, Urologic oncology.
[102] G. Bosl,et al. Surgery of Testicular Tumors , 2012 .
[103] P. Albers,et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. , 2009, European urology.
[104] C. Catton,et al. Management of stage II seminoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] M. Jewett,et al. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy. , 1998, Seminars in oncology.
[106] R. Motzer,et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. , 1998, The Journal of urology.
[107] R. Motzer,et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] D. Dearnaley,et al. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. , 1994, The Journal of urology.
[109] J. Donohue,et al. Stage A nonseminomatous testis carcinoma: rationale and results of nerve-sparing retroperitoneal lymphadenectomy. , 1991, Urologia internationalis.
[110] S. Fosså,et al. Unilateral retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumor in clinical stage I. , 1984, European urology.
[111] E. Sayegh,et al. Roentgenographic visualization of human testicular lymphatics: a preliminary report. , 1963, The Journal of urology.